Efficiency of Ustekinumab in Crohn's Disease with Severe Psoriasiform Rash Induced by Biotherapies in an Adolescent | Zendy

Bertrand Valérie | Zendy; El Haite Abdelaziz | Zendy; Carré Delphine | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Efficiency of Ustekinumab in Crohn's Disease with Severe Psoriasiform Rash Induced by Biotherapies in an Adolescent

Author(s) -

Bertrand Valérie,

El Haite Abdelaziz,

Carré Delphine

Publication year - 2017

Publication title -

pediatric dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.542

H-Index - 73

eISSN - 1525-1470

pISSN - 0736-8046

DOI - 10.1111/pde.13138

Subject(s) - ustekinumab , medicine , psoriasis , dermatology , rash , crohn's disease , crohn disease , disease , adalimumab

Ustekinumab is approved for the treatment of psoriasis in adolescents and for the treatment of moderate to severe Crohn's disease ( CD ) in adults, but data are lacking in pediatric CD . We report a case of severe psoriasis induced by biotherapies in an adolescent with CD that improved after switching to ustekinumab (90 mg at weeks 0, 2, and 4 and then every 8 weeks). The patient had not experienced CD relapse after 1 year of follow‐up. Ustekinumab can be an alternative therapy for psoriasis induced by biotherapies when conventional treatment fails and can maintain remission of CD .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research